Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538028 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
A Phase 1 study, sponsored by Incyte Biosciences International Sàrl.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03538028 is a Phase 1 study that has completed, run by Incyte Biosciences International Sàrl. The registered enrollment target is 22 participants.
The verdict
NCT03538028, a Phase 1 study, has completed, sponsored by Incyte Biosciences International Sàrl.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
Interventions
- BIOLOGICAL INCAGN02385
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2020-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03538028
The ClinicalTrials.gov registry entry for NCT03538028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Biosciences International Sàrl, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCAGN02385 is the first listed.
NCT03538028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03538028 about?
NCT03538028 is a clinical study titled "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies". The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
What is the current status of trial NCT03538028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-06-18. Estimated completion is 2020-10-07.
What interventions are being tested in trial NCT03538028?
The interventions under investigation include: INCAGN02385 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03538028?
This trial is sponsored by Incyte Biosciences International Sàrl, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.